Mission BioCapital, in collaboration with an expanded syndicate of global partners including Connecticut Innovations, has officially opened applications for its 2026 Platinum Program. This international initiative is designed to identify and support high-potential, early-stage biotechnology startups with the resources needed for rapid growth. Innovators worldwide are invited to apply for pre-seed funding, laboratory space, and expert mentorship between April 1 and May 15, 2026.
A Global Collaboration for Biotech Innovation
The 2026 program features an expanded roster of sponsors, with AbbVie, Toronto Innovation Acceleration Partners, and Connecticut Innovations joining existing partners like Ono Venture Investment. This powerful collaboration aims to provide comprehensive support to accelerate the launch and development of promising life sciences companies. The initiative's international scope underscores a collective commitment to fostering breakthrough science on a global scale.
Successful applicants, with up to eight winners selected, will receive a substantial support package to de-risk their initial development phase. This includes up to $500,000 in pre-seed capital and a guaranteed lab bench in one of 31 affiliated incubators across North America, Europe, and Japan. The award also provides critical drug discovery services from Alloy Therapeutics and HitGen, alongside expert legal and financial counsel.
Strengthening Connecticut's Life Sciences Hub
Connecticut Innovations' new partnership in the program reinforces the state's commitment to becoming a premier destination for life sciences innovation. Brian Dowd, director of investments at CI, emphasized that the collaboration provides founders with the essential resources to transform high-quality concepts into successful companies. This strategic involvement is designed to anchor emerging biotech ventures within Connecticut’s growing ecosystem.
Startups participating through the program will gain unparalleled access to Connecticut's robust innovation network, including its top-tier research institutions and experienced industry operators. CI will further support these companies by connecting them to vital follow-on funding opportunities within the state. This initiative is a key component of CI's broader strategy to attract, build, and scale high-growth companies in the region.
A Proven Track Record of Success
Since its inception in 2022, the Platinum Program has established a strong record of successfully launching new ventures. According to Jennifer Griffin, a partner at Mission BioCapital, the program has already supported 24 exceptional founders by deploying $11.5 million in pre-seed funding. This history of hands-on support has been instrumental in helping entrepreneurs turn novel scientific ideas into tangible medical breakthroughs.
The success of the program is exemplified by its diverse alumni, including the nine winners of the 2025 cohort. These companies are tackling challenges ranging from preeclampsia to metabolic diseases and oncology, with ventures located in global hubs like Copenhagen, Paris, and San Francisco. Notably, the cohort includes State 4 Therapeutics, a New Haven-based company developing therapies for weight loss, highlighting the program's local impact.
The 2026 Platinum Program represents a significant opportunity for biotechnology innovators to accelerate their journey from concept to commercialization. With applications closing on May 15, 2026, the initiative stands as a testament to the power of collaborative investment in the future of medicine. This global effort not only propels individual startups forward but also strengthens key life sciences ecosystems like Connecticut.